Illumina adds former Labcorp CEO David P. King to its Board to boost clinical genomics strategy.

Illumina has appointed David P. King, former Chairman and CEO of Labcorp, to its Board of Directors. King's extensive healthcare and diagnostics experience is expected to strengthen Illumina's efforts to integrate genomics into standard clinical care. His leadership background includes growing Labcorp significantly through organic growth and acquisitions. This strategic move comes as Illumina aims to enhance its impact on patient care and shareholder value.